Pre-clinical and Discovery stage candidates This report covers around 300+ products under different phases of clinical development likeĮarly-stage product (Phase I), along with the details of The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc. It navigates the major collaborations (company-company collaborations and company-academia collaborations), licensing agreements, financing details, data presentation by the pharma giants, and regulatory approval in the CAR T-Cell Therapy market. The report evaluates the drugs that are under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type. It outlines the key companies involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. It accesses the different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development. The report provides detailed insights into emerging CAR T-Cell Therapies and the aggregate therapies developed by major pharma companies. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers, acquisition, funding, designations, and other product-related details.Ĭhimeric Antigen Receptor T-Cell Therapy (CAR-T) Pipeline Analysis The CAR T-Cell Therapy Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. “ Chimeric Antigen Receptor T-Cell Therapy (CAR-T) Pipeline Insight, 2022” report by DelveInsight outlines a comprehensive assessment of the present clinical/non-clinical development activities and growth prospects across the CAR T-Cell Therapy Market. Several of the therapies are in the advanced stages of clinical development and are expected to launch in the coming years.Īs per DelveInsight, Chimeric Antigen Receptor T-Cell Therapy (CAR-T) market is expected to evolve immensely in the coming years owing to the increasing incidence of cancer types (ALL, NHL, MM, Prostate cancer, breast cancer, among others) and the ongoing research and development activities in the therapeutics landscape. Globally, about 300+ prominent pharma and biotech companies are working on 300+ pipeline drugs in the CAR T-cell Therapy landscape.
0 kommentar(er)
